Adial Pharmaceuticals falls after quarterly loss widens

Adial Pharmaceuticals

17/08/2026 12:38

** Shares of drug developer Adial Pharmaceuticals ADIL.O fall 22.6% to $3.08 premarket 
** Co's Q2 loss widens to $11.25 per share from $4.61 a year earlier
** Net loss widens to $52 million from $2 million, mainly due to a $46.2 million non-cash charge tied to the acquisition of Azora Therapeutics and higher administrative expenses
** ADIL completed the acquisition of Azora, adding experimental ulcerative colitis drug AT177 and shifting its focus to inflammatory diseases
** Co plans to seek approval to begin clinical testing of AT177 in H1 2027, with an early-stage trial expected to start in H2 2027
** As of last close, ADIL down 27.6% YTD 

 (Reporting by Kunal Das in Bengaluru)
 ((Kunal.Das2@thomsonreuters.com;))